Bacteria can stick together to form slimy sheets called biofilms that yellow people's teeth, line the
lungs of cystic fibrosis patients and often resist antibiotics.
Although scientists first mapped the genetic structure of P. aeruginosa 15 years ago, efforts to pinpoint how it behaves during an infection and which genes would need to be turned off to stop its spread have been hampered in part by the difficulty of mimicking the unique
conditions of a cystic fibrosis patient's lungs.
Although Kalydeco has so far been approved only for 4 per
cent of cystic fibrosis patients, who carry a specific mutation, the three drugs together could treat more than 90 per cent of people with the disease.
While PUR1900 has the potential to improve the
lives of cystic fibrosis patients, especially children and young adults, it also could bring significant revenues for Pulmatrix.
That raises the possibility of using them to treat infections caused by biofilms, such as the Pseudomonas aeruginosa infections that often affect the
lungs of cystic fibrosis patients.
42) Schwank, G., Koo, B.K., Sasselli, V., Dekkers, J.F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C.K., Nieuwenhuis, E.E., Beekman, J.M. and Clevers, H. Functional repair of CFTR by CRISPR / Cas9 in intestinal stem cell
organoids of cystic fibrosis patients.
Staphylococcus aureus and Pseudomonas aeruginosa commonly co-infect wounds, catheters and lungs
of cystic fibrosis patients.
Substances produced by a harmful bacterium in the lungs
of cystic fibrosis patients may enhance the growth of other bacteria that, in turn, inhibit the harmful bacterium's biofilm, according to new research.
Substances produced by a harmful bacterium in the lungs
of cystic fibrosis patients may enhance the growth of other bacteria that, in turn, inhibit the harmful bacterium's biofilm, according to new research published in PLOS Pathogens.
These findings suggest a potential mechanism by which S. parasanguinis, which is normally found on the surface of teeth, might colonize the lungs
of a cystic fibrosis patient and inhibit P. aeruginosa.
To make these cracks, the researchers turned to Pseudomonas aeruginosa — a bacterial species that often builds biofilms within the lungs
of cystic fibrosis patients, which can lead to chronic obstructive pulmonary disease and subsequently death.
How do microbes duke it out in the lungs
of cystic fibrosis patients?
The first of many probable applications will likely be the chronic bacterial infections in the lungs
of cystic fibrosis patients «that frequently develop resistance to all standard antibiotics, and are the leading cause of death in these patients,» says senior author Ronald Montelaro.
In the past, researchers studied Pseudomonas in isolation despite the fact that it's rarely the lone bacterium in the lungs of people with CF. Hoffman decided to study how Pseudomonas and Staphylococcus aureus — the other bacterium most commonly found in the lungs
of cystic fibrosis patients — behave when the two are grown together.
We also sequenced several members of the Burkholderia cenocepacia complex that are important pathogens in the lungs
of cystic fibrosis patients.